Altimmune, Inc. (Nasdaq: ALT), a Gaithersburg, MD-based clinical-stage immunotherapeutics company, closed the previously announced underwritten public offering of common units and pre-funded units for gross proceeds of $12m.
Together with the company’s registered direct offering announced on September 24 – a $4.9m registered direct offering closed September 26 – the company received aggregate gross proceeds of $16.9m.
The proceeds will continue the development of NasoVax and other product candidates.
Led by William J. Enright, President and CEO, Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate durable immune responses for the prevention and treatment of infectious disease. The company’s products include:
- NasoVAX, an influenza vaccine candidate, and
- NasoShield is an anthrax vaccine candidate.
FinSMEs
08/10/2018